Seyoum Ayehunie

Dr. Seyoum Ayehunie


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
IMIlka Maschmeyer
Ilka Maschmeyer
THTobias Hasenberg
Tobias Hasenberg
AJAnnika Jaenicke
Annika Jaenicke
MLMarcus Lindner
Marcus Lindner
ALAlexandra Katharina Lorenz
Alexandra Katharina Lorenz
EMEva-Maria Materne
Eva-Maria Materne

1 August 2006 in Toxicology in Vitro
Verified
Journal Article
Closed access
SASeyoum Ayehunie
Seyoum Ayehunie
CCChris Cannon
Chris Cannon
SLSarah Lamore
Sarah Lamore
JKJoseph Kubilus
Joseph Kubilus
DADeborah J. Anderson
Deborah J. Anderson
MKMitchell Klausner
Mitchell Klausner

28 June 2017 in Gut Microbes
Verified
Journal Article
Closed access
AMAna Maldonado-Contreras
Ana Maldonado-Contreras
JBJames R. Birtley
James R. Birtley
EBErik Boll
Erik Boll
YZYun Zhao
Yun Zhao
KMKaren L. Mumy
Karen L. Mumy
BMBeth A. McCormick
Beth A. McCormick
Shigella is unique among enteric pathogens, as it invades colonic epithelia through the basolateral pole. Therefore, it has evolved the ability to breach the intestinal epithelial barrier to deploy an arsenal of effector proteins, which permits bacterial invasion and leads to a severe inflammatory response. However, the mechanisms used by Shigella to regulate epithelial barrier permeability remain unknown. To address this question, we used both an intestinal polarized model and a human ex-vivo model to further characterize the early events of host-bacteria interactions. Our results showed that secreted Serine Protease A (SepA), which belongs to the serine protease autotransporter of Enterobacteriaceae family, is responsible for critically disrupting the intestinal epithelial barrier. Such disruption facilitates bacterial transit to the basolateral pole of the epithelium, ultimately fostering the hallmarks of the disease pathology. SepA was found to cause a decrease in active LIM Kinase 1 (LIMK1) levels, a negative inhibitor of actin-remodeling proteins, namely cofilin. Correspondingly, we observed increased activation of cofilin, a major actin-polymerization factor known to control opening of tight junctions at the epithelial barrier. Furthermore, we resolved the crystal structure of SepA to elucidate its role on actin-dynamics and barrier disruption. The serine protease activity of SepA was found to be required for the regulatory effects on LIMK1 and cofilin, resulting in the disruption of the epithelial barrier during infection. Altogether, we demonstrate that SepA is indispensable for barrier disruption, ultimately facilitating Shigella transit to the basolateral pole where it effectively invades the epithelium.

23 February 2018 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
SASeyoum Ayehunie
Seyoum Ayehunie
TLTim Landry
Tim Landry
ZSZachary Stevens
Zachary Stevens
AAAlex Armento
Alex Armento
PHPatrick Hayden
Patrick Hayden
MKMitchell Klausner
Mitchell Klausner

1 January 2019 in Carbohydrate Polymers
Verified
Journal Article
Closed access
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya
Snehal ShuklaSnehal Shukla
Snehal Shukla
SKSrikanth Kolluru
Srikanth Kolluru
MHMelanie Huen
Melanie Huen
NMNihal Mulla
Nihal Mulla
Vivek GuptaVivek Gupta
Vivek Gupta

25 November 2020 in In Vitro Cellular & Developmental Biology - Animal
Verified
Journal Article
Closed access
PDF file
JMJan Markus
Jan Markus
TLTim Landry
Tim Landry
ZSZachary Stevens
Zachary Stevens
HSHailey Scott
Hailey Scott
PLPierre Llanos
Pierre Llanos
SASeyoum Ayehunie
Seyoum Ayehunie